{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:19:55Z","timestamp":1772169595951,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clgc.2018.05.003","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T12:18:08Z","timestamp":1526473088000},"page":"328-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223"],"prefix":"10.1016","volume":"16","author":[{"given":"Bente Brokstad","family":"Herlofson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gry Karina","family":"Kj\u00f8lle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine L\u00f8ken","family":"Westgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayca M.","family":"L\u00f8ndalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8yvind S.","family":"Bruland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2018.05.003_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bdj.2015.680","article-title":"New cancer therapies and jaw necrosis","volume":"219","author":"Patel","year":"2015","journal-title":"Br Dent J"},{"key":"10.1016\/j.clgc.2018.05.003_bib2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2018.05.003_bib3","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2018.05.003_bib4","first-page":"406","article-title":"Osteogenic sarcoma in dial painters using luminous paint","volume":"7","author":"Martland","year":"1973","journal-title":"Arch Pathol"},{"key":"10.1016\/j.clgc.2018.05.003_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/scientificamerican0893-94","article-title":"The great radium scandal","volume":"269","author":"Macklis","year":"1993","journal-title":"Sci Am"},{"key":"10.1016\/j.clgc.2018.05.003_bib6","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2018.05.003_bib7","author":"United States Food and Drug Administration"},{"key":"10.1016\/j.clgc.2018.05.003_bib8","author":"European Medicines Agency"},{"key":"10.1016\/j.clgc.2018.05.003_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.05.003_bib10","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2018.05.003_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.eururo.2017.06.021","article-title":"Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in Symptomatic Prostate Cancer Trial","volume":"73","author":"Parker","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2018.05.003_bib13","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/j.clgc.2016.12.028","article-title":"Acute promyelocytic leukemia after treatment of metastatic castration-resistant prostate cancer with Radium-223","volume":"15","author":"Odo","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2018.05.003_bib14","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1016\/j.clgc.2016.11.002","article-title":"Acute myeloid leukemia after radium-223 therapy: case report","volume":"15","author":"Varkaris","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2018.05.003_bib15","first-page":"CD012432","article-title":"Interventions for managing medication-related osteonecrosis of the jaw (Review)","volume":"10","author":"Beth-Tasdogan","year":"2017","journal-title":"Cochrane Database of Syst Rev"},{"key":"10.1016\/j.clgc.2018.05.003_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1634\/theoncologist.2010-0183","article-title":"Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw","volume":"16","author":"Miksad","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2018.05.003_bib17","first-page":"3527","article-title":"Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires","volume":"32","author":"Kyrgidis","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2018.05.003_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40264-017-0582-6","article-title":"Treatment of medication-related osteonecrosis of the jaw and its impact on a patient\u2019s quality of life: a single-center, 10-year experience from Southern Italy","volume":"41","author":"Oteri","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.clgc.2018.05.003_bib19","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1248\/bpb.b15-00385","article-title":"Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study","volume":"38","author":"Kajizono","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.clgc.2018.05.003_bib20","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1210\/jc.2015-1794","article-title":"Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer","volume":"100","author":"Sim","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2018.05.003_bib21","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jcms.2016.07.026","article-title":"Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid \u2013 a prospective study over 6 years","volume":"44","author":"M\u00fccke","year":"2016","journal-title":"J\u00a0Cranio-Maxillo-Fac Surg"},{"key":"10.1016\/j.clgc.2018.05.003_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.oooo.2018.02.003","article-title":"Medication-related osteonecrosis of the jaw: an update on the Memorial Sloan Kettering Cancer Center experience and the role of premedication dental evaluation in prevention","volume":"125","author":"Owosho","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318303641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318303641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:29:29Z","timestamp":1761564569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318303641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1558767318303641"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.05.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}